Want to see ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
$120.16
-$0.09(-1.29%)
At close: 4:00 PM EST
$120.16
-$0.09(-1.29%)
Day’s Range― - ―
52-Week Range$5.69 - $148.83
Previous CloseN/A
Volume62.24K
Average Volume (3M)2.28M
Market Cap
$12.31B
Enterprise Value$6.57B
Total Cash (Recent Filing)$530.16M
Total Debt (Recent Filing)$45.89M
Price to Earnings (P/E)―
Beta2.78
Next Earnings
Sep 21, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding79,782,940
10 Day Avg. Volume1,681,684
30 Day Avg. Volume2,275,277
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)17.54
Price to Sales (P/S)0.00
P/FCF Ratio-51.21
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.86
Forecast
1Y Price Target
$156.75Price Target Upside30.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.83
Revenue Forecast (FY)$4.36M
Bulls Say, Bears Say
Bulls Say
Stronger Balance SheetAbivax’s materially de-levered balance sheet and expanded asset base provide durable financial resilience. Low debt reduces refinancing risk and gives management flexibility to fund late-stage trials and U.S. commercialization prep without immediate reliance on expensive borrowings, supporting multi-quarter strategic execution.
Positive Phase 3 Maintenance DataRobust maintenance results in a refractory UC cohort strengthen the clinical profile and broaden target population. Demonstrated remission and recapture support a durable label and payer acceptance, raise regulatory approval probability for an NDA, and underpin long-term commercial potential if safety remains acceptable.
Major Equity Raise Strengthens RunwayThe large public offering meaningfully extends financial flexibility, reducing near-term funding pressure and enabling completion of registrational activities and commercialization investments. This structural capital buffer lowers immediate dilution risk from smaller raises and allows prioritized spending on launch-readiness and additional indications.
Bears Say
Zero 2025 Revenue And Widening LossesThe absence of product revenue and rapidly widening net losses mean Abivax remains wholly dependent on external financing and future regulatory success. Persisting negative profitability erodes equity over time and makes long-term viability contingent on approval/commercialization of obefazimod or successful launch outcomes.
High Cash BurnSustained negative operating and free cash flow reflect intensive trial and development spending. Even with recent capital, ongoing burn requires strict prioritization: continued high cash consumption increases dilution risk over the medium term if clinical or regulatory timelines slip or commercialization ramps slower than planned.
Concentration And Safety ObservationsBusiness is highly concentrated on a single late-stage asset, so residual safety signals amplify binary outcome risk. Any adverse regulatory interpretation or prescriber caution around malignancy observations could constrain label, uptake, and reimbursement, materially affecting long-term revenue prospects if not fully resolved in the safety database.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $5.69 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $12.31B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Sep 21, 2026 which is in 77 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on May 22, 2026. The company reported -$0.708 earnings per share for the quarter, beating the consensus estimate of -$0.936 by $0.228.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.82.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 79,782,940 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$0.708 in its last earnings report, beating expectations of -$0.936. Following the earnings report the stock price went up 3.623%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$156.75 (30.45% Upside)
$156.75 (30.45% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 487.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1764.04%
12-Months-Change
Fundamentals
Return on Equity
-165.19%
Trailing 12-Months
Asset Growth
249.60%
Trailing 12-Months
Company Description
Abivax SA Sponsored ADR
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$156.75
▲(30.45% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
―
Insiders
5.98% Mutual Funds
40.20% Other Institutional Investors
52.89% Public Companies and Individual Investors